Elanco Animal Health Incorporated today announced U.S. Department of Agriculture (USDA) approval of TruCan™ Ultra B (Oral), an innovative oral vaccine designed to help protect dogs against Bordetella bronchiseptica, one of the primary pathogens associated with canine infectious respiratory disease…
Almirall, a global pharmaceutical company focused exclusively on medical dermatology, has announced plans to initiate a Phase III clinical study evaluating the efficacy and safety of lebrikizumab in adult patients with nummular eczema. The study, named LumiNE, is scheduled to…
Orion Revamps Packaging to Boost Patient Experience and Sustainability Since 2020, Orion has been systematically reimagining its product packaging with a dual focus on patient safety and environmental sustainability. This ongoing effort has touched every stage of the supply chain—from…
argenx SE a global immunology company focused on transforming outcomes for patients with severe autoimmune diseases, has announced a significant regulatory milestone for its flagship therapy, VYVGART® (IV: efgartigimod alfa-fcab). The U.S. Food and Drug Administration (FDA) has accepted the…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for…
DESTINY-Breast05 Phase III Trial Demonstrates ENHERTU® Significantly Reduces Recurrence Risk in High-Risk HER2-Positive Early Breast Cancer Positive results from the DESTINY-Breast05 Phase III trial have demonstrated that ENHERTU® (fam-trastuzumab deruxtecan-nxki) provides a highly statistically significant and clinically meaningful improvement in…
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Shows Durable 5-Year Survival Benefit Over Chemotherapy in Advanced Endometrial Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced updated five-year follow-up data from the pivotal Phase…
Water- en Energiebedrijf Aruba N.V. (WEB) and Seven Seas Water Group, a leading multinational provider of Water-as-a-Service® (WaaS®) solutions, have officially broken ground on a new state-of-the-art seawater reverse osmosis (SWRO) desalination plant in Aruba. The project marks a major…
Diorasis Therapeutics, a biotechnology company pioneering durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Dimitri Azar, MD, MBA, AM (hon.), DHL (hon.), to its Board of Directors. Dr. Azar is a globally recognized leader…
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, operating in the U.S. and Canada, has announced a landmark agreement with the administration of President Donald J. Trump to broaden access to in vitro fertilization (IVF) therapies for the…